

Musculoskeletal Infections Clinical Practice Guidelines
Monroe Carell Jr. Children's Hospital at Vanderbilt
2020

References

1. Chou, ACC, Mahadev A. The use of c-reactive protein as a guide for transitioning to oral antibiotics in pediatric osteoarticular infections. *J Pediatr Orthop*, 2016.
2. Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, Hallesy JA, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant *Staphylococcus aureus* bloodstream infections. *Antimicrobial Agents and Chemotherapy*, 2016.
3. Foglar C and Lindsey RW. C-reactive protein in orthopedics. *Orthopedics*, 1998.
4. Howard-Jones AR and Isaacs D. Systematic review of duration and choice of systemic antibiotic therapy for acute haematogenous bacterial osteomyelitis in children. *J Pediatric and Child Health*, 2013.
5. Keren R, Shah SS, Srivastava R, Rangel S, Bendel-Stenzel M, Harik N, Hartley J, Lopez M, Seguias L, Tieder J, Bryan M, Gong W, Hall M, Localio R, Luan X, deBerardinis R, Parker A; for the Pediatric Research in Inpatient Settings Network. Comparative effectiveness of intravenous vs oral antibiotics for postdischarge treatment of acute osteomyelitis in children. *JAMA Pediatr*, 2015.
6. Kullar R, Davis SL, Kaye KS, Levine DP, Pogue JM and Rybak MJ. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *Pharmacotherapy*, 2013.
7. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA and Chambers HF. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *CID*, 2011.
8. McMichael BS, Nickel AJ, Christensen EW, Frenn KA, Truong WH, Laine JC and Kharbanda AB. Discriminative accuracy of procalcitonin and traditional biomarkers in pediatric acute musculoskeletal infection. *Pediatric Emergency Care*, 2020.
9. Messina AF, Namtu K, Guild M, Dumois JA, and Berman DM. Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis, *PIDJ* 2011.
10. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P and Rybak MJ. Early use of daptomycin versus vancomycin for methicillin-resistant *Staphylococcus aureus* bacteremia with vancomycin minimum inhibitory concentration > 1 mg/L: A matched cohort study. *CID*, 2013.

11. Paakkonen M, Kallio PE, Kallio MJT and Peltola H. Does bacteremia associated with bone and joint infections necessitate prolonged parental antimicrobial therapy? *JPIDS*, 2015.
12. Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, Girschick H, Hartwig N, Kaplan S, Lorrot M, Mantadakis E, Peltola H, Rojo P, Zaoutis T and LeMair A. The European Society for Pediatric Infectious Diseases (ESPID) Bone and Joint Infection Guidelines. *The Pediatric Infectious Disease Journal*, 2017.
13. Spruiell MD, Searns JB, Heare TC, Roberts JL, Wylie E, Pyle L, Donaldson N, Steward JR, Heizer H, Reese J, Scott HF, Pearce K, Anderson CJ, Erickson M and Parker SK. Clinical care guideline for improving pediatric acute musculoskeletal infection outcomes. *JPIDS*, 2017.
14. Zaoutis T, Localio AR, Leckerman K, Saddlemire S, Bertoch D and Keren R. Prolonged intravenous therapy versus early transition to oral antimicrobial therapy for acute osteomyelitis in children. *Pediatrics*, 2009.